Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy
Read More
Tag: Epidiolex
Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn
Jazz will add GW’s plant-derived cannabinoid treatment Epidiolex to its roster
Read More
NICE to work with GW Pharma after Epidiolex rejection
The committee also cited concerns about the economic models provided by the company.
Read More
GW Pharmaceuticals announce quarterly financial results
GW Pharmaceuticals has reported revenue growth of 67.5% for the fourth quarter, driven by demand for Epidiolex.
Read More
GW Pharma’s Epidiolex nears US launch
GW Pharmaceuticals and its subsidiary Greenwich Biosciences are gearing up to launch Epidiolex in the US after drug enforcement officials re-classified the cannabis-based medicine to the lowest restriction.
Read More
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Read More
GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
Read More
GW’s cannabidiol gets EU orphan status for TS
GW Pharma’s cannabidiol (CBD) has been granted orphan drug designation by European regulators for the treatment of tuberous sclerosis (TS).
Read More
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
Read More
GW’s cannabinoid Epidiolex under EU, US review
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Read More
GW Pharma poised to file Epidiolex in the US
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
